A Study of Gaboxadol in Primary Insomnia
A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia
1 other identifier
interventional
600
0 countries
N/A
Brief Summary
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jun 2003
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2003
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 13, 2005
CompletedFirst Posted
Study publicly available on registry
September 21, 2005
CompletedMarch 30, 2007
March 1, 2007
September 13, 2005
March 29, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Long-term safety in gaboxadol.
Interventions
Eligibility Criteria
You may qualify if:
- patients with Primary insomnia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- H. Lundbeck A/Slead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Please contact: Annelies van der Hammen Legters
H. Lundbeck A/S
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 13, 2005
First Posted
September 21, 2005
Study Start
June 1, 2003
Study Completion
March 1, 2005
Last Updated
March 30, 2007
Record last verified: 2007-03